Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELUTNASDAQ:INCRNASDAQ:JSPRNASDAQ:PIRS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELUTElutia$1.80+9.1%$2.15$1.61▼$5.24$74.01M0.9750,521 shs11,788 shsINCRInterCure$1.59+0.6%$1.45$1.17▼$3.00$71.42M1.2528,243 shs9,964 shsJSPRJasper Therapeutics$5.55-2.3%$4.55$3.13▼$26.84$82.62M2.74296,886 shs174,300 shsPIRSPieris Pharmaceuticals$13.60$15.17$6.20▼$18.68$17.95M0.6173,489 shs51,728 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELUTElutia0.00%+4.65%-18.55%-45.12%-45.78%INCRInterCure0.00%+2.58%+2.58%+1.27%-49.20%JSPRJasper Therapeutics0.00%+16.35%+3.16%-6.41%-77.09%PIRSPieris Pharmaceuticals0.00%0.00%0.00%0.00%+41.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELUTElutia3.3028 of 5 stars3.54.00.00.02.63.30.6INCRInterCure0.3895 of 5 stars0.03.00.00.01.90.00.6JSPRJasper Therapeutics2.2368 of 5 stars3.51.00.00.03.41.70.6PIRSPieris PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELUTElutia 3.00Buy$8.00344.44% UpsideINCRInterCure 0.00N/AN/AN/AJSPRJasper Therapeutics 3.00Buy$62.221,021.12% UpsidePIRSPieris Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PIRS, JSPR, INCR, and ELUT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025JSPRJasper TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$80.00 ➝ $65.005/13/2025JSPRJasper TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $33.005/9/2025ELUTElutiaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.003/11/2025JSPRJasper TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/7/2025ELUTElutiaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$8.00 ➝ $8.00(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELUTElutia$23.71M3.12N/AN/A($1.66) per share-1.08INCRInterCure$238.85M0.30N/AN/A$2.72 per share0.58JSPRJasper TherapeuticsN/AN/AN/AN/A$7.03 per shareN/APIRSPieris Pharmaceuticals$42.81M0.42N/AN/A$21.66 per share0.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELUTElutia-$37.66M-$1.93N/AN/AN/A-218.72%N/A-142.61%7/28/2025 (Estimated)INCRInterCure-$16.83MN/A0.00∞N/AN/AN/AN/AN/AJSPRJasper Therapeutics-$64.46M-$5.24N/AN/AN/AN/A-67.64%-58.53%8/12/2025 (Estimated)PIRSPieris Pharmaceuticals-$24.54M-$12.10N/A∞N/A-39.71%-80.93%-59.55%N/ALatest PIRS, JSPR, INCR, and ELUT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025JSPRJasper Therapeutics-$1.17-$1.41-$0.24-$1.41N/AN/A5/8/2025Q1 2025ELUTElutia-$0.20-$0.21-$0.01-$0.21$6.65 million$6.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELUTElutiaN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/APIRSPieris PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELUTElutiaN/A0.940.85INCRInterCure0.151.781.15JSPRJasper TherapeuticsN/A7.617.61PIRSPieris PharmaceuticalsN/A4.824.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELUTElutia74.03%INCRInterCure8.34%JSPRJasper Therapeutics79.85%PIRSPieris Pharmaceuticals40.11%Insider OwnershipCompanyInsider OwnershipELUTElutia27.60%INCRInterCure0.24%JSPRJasper Therapeutics4.60%PIRSPieris Pharmaceuticals6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELUTElutia18041.12 million20.46 millionNot OptionableINCRInterCure35045.57 million45.46 millionOptionableJSPRJasper Therapeutics2015.02 million14.60 millionOptionablePIRSPieris Pharmaceuticals1401.32 million1.24 millionOptionablePIRS, JSPR, INCR, and ELUT HeadlinesRecent News About These CompaniesPieris Pharmaceuticals IncApril 19, 2025 | money.usnews.comPalvella Therapeutics Inc (PVLA)December 27, 2024 | investing.comMain Line biotech firm completes reverse merger, raises $78.9 millionDecember 17, 2024 | bizjournals.comOne new option listing and one option delisting on December 16thDecember 17, 2024 | markets.businessinsider.comPalvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease TreatmentsDecember 14, 2024 | msn.comPalvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 MillionDecember 14, 2024 | markets.businessinsider.com(PIRS) Trading ReportNovember 28, 2024 | news.stocktradersdaily.comPIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRSNovember 20, 2024 | businesswire.comHow To Trade (PIRS)November 17, 2024 | news.stocktradersdaily.comPieris Pharmaceuticals announces first patient dosed in SELVA Phase 3 trialNovember 7, 2024 | markets.businessinsider.com(PIRS) Investment Analysis and AdviceNovember 6, 2024 | news.stocktradersdaily.comPieris loses Servier as partner for cancer immunotherapiesOctober 29, 2024 | pharmaphorum.com(PIRS) Technical DataOctober 27, 2024 | news.stocktradersdaily.comAridis Pharmaceuticals (OTC:ARDS) Stock Quotes, Forecast and News SummaryOctober 19, 2024 | benzinga.comLearn to Evaluate (PIRS) using the ChartsOctober 16, 2024 | news.stocktradersdaily.comPalvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual ConferenceOctober 15, 2024 | globenewswire.com(PIRS) Trading SignalsOctober 7, 2024 | news.stocktradersdaily.comPalvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic MalformationsOctober 3, 2024 | globenewswire.comKubota Pharmaceutical Holdings Co., Ltd. (4596.T) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comPieris Pharmaceuticals Inc.September 24, 2024 | barrons.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines5 Small-Cap Stocks to Watch for Big Speculative GainsBy Thomas Hughes | May 21, 2025View 5 Small-Cap Stocks to Watch for Big Speculative Gains3 Companies That Just Raised Dividends; 2 to Buy, 1 to AvoidBy Chris Markoch | May 19, 2025View 3 Companies That Just Raised Dividends; 2 to Buy, 1 to AvoidLockheed Martin: A Top Defense Pick in 2025By Jeffrey Neal Johnson | May 16, 2025View Lockheed Martin: A Top Defense Pick in 2025AMD’s AI-Powered Stock Price Rally Just Shifted GearsBy Thomas Hughes | May 14, 2025View AMD’s AI-Powered Stock Price Rally Just Shifted Gears3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%PIRS, JSPR, INCR, and ELUT Company DescriptionsElutia NASDAQ:ELUT$1.80 +0.15 (+9.09%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.80 0.00 (0.00%) As of 05/30/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.InterCure NASDAQ:INCR$1.59 +0.01 (+0.63%) Closing price 05/30/2025 03:55 PM EasternExtended Trading$1.61 +0.02 (+1.32%) As of 05/30/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Jasper Therapeutics NASDAQ:JSPR$5.55 -0.13 (-2.29%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$5.38 -0.18 (-3.15%) As of 05/30/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.Pieris Pharmaceuticals NASDAQ:PIRSPieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
